Pertussis vaccination and the risk of respiratory syncytial virus-associated hospitalization

Pediatric Infectious Disease Journal

Volumn 23, Issue 10, 2004, Pages 897-901

  Boyce, Thomas G ^a   Weaver, Amy L ^a   St Sauver, Jennifer L ^a   Woodward Lee, Astrid E ^a   Stancl, Judy K ^a   Park, Jin Young ^a   Jacobsen, Steven J ^a   Jacobson, Robert M ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Diphtheria tetanus acellular pertussis vaccine; Immunization; Pertussis; Respiratory syncytial virus; Vaccine

Indexed keywords

PERTUSSIS VACCINE;

ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HOSPITALIZATION; HUMAN; IMMUNIZATION; INFANT; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; OXYGEN CONSUMPTION; PERTUSSIS; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; VIRUS INFECTION; CASE CONTROL STUDY; PATHOPHYSIOLOGY;

CASE-CONTROL STUDIES; HOSPITALIZATION; HUMANS; INFANT; PERTUSSIS VACCINE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS;

EID: 16544364892     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000141725.45280.6c     Document Type: Article

References (23)

1. Fischer JE, Johnson TR, Peebles RS, Graham BS. Vaccination with pertussis toxin alters the antibody response to simultaneous respiratory syncytial virus challenge. J infect Dis. 1999;180:714-719.
2. Fischer JE, Johnson JE, Johnson TR, Graham BS. Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infection. J Infect Dis. 2000;182:1029-1038.
3. Simoes EA. Respiratory syncytial virus infection. Lancet. 1999;354: 847-852.
4. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137:865-870.
5. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422-434.
6. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969;89:405-421.
7. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization, I: a field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969;89:435-448.
8. Graham BS. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. Am J Respir Crit Care Med. 1995;152:S63-S66.
9. Welliver RC, Wong DT, Sun M, Middleton E Jr, Vaughan RS, Ogra PL. The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. N Engl J Med. 1981;305:841-846.
10. Poland GA. Acellular pertussis vaccines: new vaccines for an old disease. Lancet. 1997;350:1564-1565.
11. Decker MD, Edwards KM. Acellular pertussis vaccines. Pediatr Clin North Am. 2000;47:309-335.
12. Munoz JJ. Action of pertussigen (pertussis toxin) on the host immune system. In: Wardlaw AC, Parton R, eds. Pathogenesis and Immunity in Pertussis. Chichester, United Kingdom: John Wiley & Sons; 1988:173-192.
13. Respiratory syncytial virus infection: admissions to hospital in industrial, urban, and rural areas: report to the Medical Research Council Subcommittee on Respiratory Syncytial Virus Vaccines. Br Med J. 1978;2:796-798.
14. Parrott RH, Kim HW, Arrobio JO, et al. Epidemiology of respiratory syncytial virus infection in Washington, DC, II: infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol. 1973;98:289-300.
15. Centers for Disease Control and Prevention. Recommended childhood immunization schedule: United States, 2000. MMWR. 2000;49:35-38.
16. Dupont WD, Plummer WD Jr. Power and sample size calculations: a review and computer program. Control Clin Trials. 1990;11:116-218.
17. + cytotoxic T lymphocyte, interferon-γ, and interleukin-4 responses to respiratory syncytial virus infection in infants and children. J Infect Dis. 2001;183:687-696.
18. Ausiello CM, Fedele G, Urbani F, Lande R, Di Carlo B, Cassone A. Native and genetically inactivated pertussis toxins induce human dendritic cell maturation and synergize with lipopolysaccharide in promoting T helper type 1 responses. J Infect Dis. 2002;186:351-360.
19. Henderson J, North K, Griffiths M, Harvey I, Golding J. Pertussis vaccination and wheezing illnesses in young children: prospective cohort study. The Longitudinal Study of Pregnancy and Childhood Team. BMJ. 1999;318:1173-1176.
20. Nilsson L, Kjellman NI, Bjorksten B. Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines. Arch Pediatr Adolesc Med. 2003;157:1184-1189.
21. Fine PE, Chen RT. Confounding in studies of adverse reactions to vaccines. Am J Epidemiol. 1992;136:121-135.
22. Frenkel LD, Nielsen K. Immunization issues for the 21st century. Ann Allergy Asthma Immunol. 2003;90:45-52.
23. Gellin BG, Schaffner W. The risk of vaccination: the importance of "negative" studies. N Engl J Med. 2001;344:372-373.